{
    "hands_on_practices": [
        {
            "introduction": "Methotrexate is a cornerstone of steroid-sparing immunosuppressive therapy for noninfectious uveitis. Initiating this therapy is more than just selecting a starting dose; it involves creating a comprehensive plan that balances efficacy with patient safety. This first practice challenges you to apply fundamental pharmacological principles to design a complete initiation protocol, from calculating the initial dose to planning for titration, supplementation, and long-term monitoring. ",
            "id": "4683321",
            "problem": "A steroid-dependent adult with noninfectious intermediate uveitis is being transitioned to a steroid-sparing immunomodulator. The patient is a $34$-year-old, $70$ kg individual with normal baseline laboratory values: complete blood count (CBC) within reference limits, alanine aminotransferase (ALT) $24$ U/L, aspartate aminotransferase (AST) $22$ U/L, and estimated glomerular filtration rate (eGFR) of $100 \\text{ mL/min/1.73 m}^2$. There is no history of chronic liver disease, hazardous alcohol use, pregnancy, or interacting medications. You plan to initiate methotrexate as once-weekly therapy.\n\nUsing foundational pharmacology principles for low-dose methotrexate in noninfectious uveitis—namely, that immunomodulatory efficacy at low doses is achieved with once-weekly administration, that dose-related toxicity is mitigated by folate supplementation, that oral absorption becomes saturable at higher weekly doses, and that safe up-titration balances efficacy with laboratory-guided monitoring—determine an appropriate initial weekly dose for a $70$ kg adult given a usual starting range of $10$ to $15$ mg/week, and outline a scientifically sound titration strategy to a maximum of $25$ mg/week, including supplementation, route considerations, and monitoring.\n\nWhich option best satisfies these requirements?\n\nA. Start $15$ mg orally once weekly (approximately $0.21$ mg/kg/week), co-prescribe folic acid $1$ mg daily (omit on the methotrexate day), and titrate by $2.5$ mg every $2$ weeks as tolerated to a maximum of $25$ mg/week; consider switching to subcutaneous administration if absorption or tolerability become limiting beyond $15$ mg; monitor CBC, liver function tests (LFTs), and serum creatinine every $4$–$8$ weeks.\n\nB. Start $10$ mg daily, co-prescribe folic acid $5$ mg twice daily, and escalate by $5$ mg/day each week to a maximum of $25$ mg/day; monitor CBC and LFTs every $6$ months.\n\nC. Start $7.5$ mg once weekly without folate, escalate by $7.5$ mg each week to $45$ mg/week; obtain weekly labs until stable.\n\nD. Start at the target dose of $25$ mg once weekly with leucovorin (folinic acid) $15$ mg given $24$ hours later and no titration; check labs quarterly only if symptoms occur.",
            "solution": "The problem statement is to determine an appropriate initiation and management plan for methotrexate therapy in a steroid-dependent adult with noninfectious intermediate uveitis, based on a set of provided pharmacological principles.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- **Diagnosis:** Steroid-dependent noninfectious intermediate uveitis.\n- **Patient:** $34$-year-old, $70$ kg adult.\n- **Baseline Labs:** CBC within reference limits, ALT $24$ U/L, AST $22$ U/L, eGFR of $100 \\text{ mL/min/1.73 m}^2$.\n- **Exclusions:** No history of chronic liver disease, hazardous alcohol use, pregnancy, or interacting medications.\n- **Proposed Medication:** Methotrexate.\n- **Core Principles:**\n    1. Once-weekly administration for immunomodulation.\n    2. Folate supplementation to mitigate dose-related toxicity.\n    3. Saturable oral absorption at higher weekly doses.\n    4. Safe up-titration with laboratory monitoring.\n- **Dosage Parameters:**\n    - Usual starting range: $10$ to $15$ mg/week.\n    - Maximum dose: $25$ mg/week.\n- **Question:** Determine the appropriate initial weekly dose, titration strategy, supplementation, route considerations, and monitoring plan.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The scenario is a standard-of-care application in clinical immunology and ophthalmology. The use of methotrexate as a first-line steroid-sparing agent for noninfectious uveitis is well-established. The provided pharmacological principles (once-weekly dosing, folate supplementation, saturable absorption, dose-titration with monitoring) are factually correct and form the basis of modern methotrexate therapy guidelines for inflammatory diseases.\n- **Well-Posed:** The problem provides sufficient, consistent information to construct a valid clinical management plan based on the stated principles. It asks for a specific output (a therapeutic plan) that can be derived from the input.\n- **Objective:** The problem is stated using precise, objective clinical and pharmacological terminology.\n- **Completeness and Consistency:** The data provided (patient weight, normal liver and kidney function) are relevant and necessary for choosing a safe starting dose and monitoring plan. There are no contradictions in the givens.\n- **Realism:** The patient case and therapeutic goals are entirely realistic and commonly encountered in clinical practice.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It is scientifically sound, well-posed, objective, and internally consistent. The solution process can proceed.\n\n### Derivation and Option Analysis\n\nBased on the provided principles and data, a scientifically sound plan for initiating methotrexate can be constructed.\n\n1.  **Dosing Regimen (Dose and Frequency):** The problem specifies a starting range of $10$ to $15$ mg/week and a a once-weekly administration schedule. For a $70$ kg adult with normal organ function, starting anywhere in this range is acceptable. Oral administration is the standard initial route. A dose of $15$ mg orally once weekly is a common and effective starting point. This corresponds to a weight-based dose of $15 \\text{ mg} / 70 \\text{ kg} \\approx 0.21$ mg/kg, which is a typical starting dose.\n\n2.  **Supplementation:** The problem mandates folate supplementation to mitigate toxicity. The standard approach is to prescribe folic acid, typically at a dose of $1$ mg daily. To avoid any theoretical interference with methotrexate efficacy, it is common practice to advise the patient to omit the folic acid dose on the day they take methotrexate.\n\n3.  **Titration Strategy:** The principle of \"safe up-titration\" requires a gradual increase in dose. Starting at the maximum dose is unsafe. A typical titration involves increasing the weekly dose by $2.5$ mg every $2$ to $4$ weeks, assessing for clinical response and monitoring for toxicity before each escalation. The target is the lowest effective dose, up to a maximum of $25$ mg/week as stated.\n\n4.  **Route of Administration:** The principle of saturable oral absorption at higher doses is critical. The bioavailability of oral methotrexate decreases at doses above $15$ mg/week. Therefore, if a patient requires a dose escalation beyond $15$ mg (or $20$ mg in some guidelines) and is not achieving the desired clinical response, or if they experience significant gastrointestinal side effects, a switch to a parenteral route (typically subcutaneous injection) is warranted to ensure complete absorption.\n\n5.  **Monitoring:** \"Laboratory-guided monitoring\" is essential to detect subclinical toxicity. Standard monitoring for low-dose methotrexate includes:\n    - **Complete Blood Count (CBC):** To monitor for myelosuppression (anemia, leukopenia, thrombocytopenia).\n    - **Liver Function Tests (LFTs):** Primarily ALT and AST, to monitor for hepatotoxicity.\n    - **Renal Function:** Serum creatinine (and/or eGFR) to ensure adequate drug clearance, as impairment increases toxicity risk.\n    Monitoring should be performed frequently after initiation and each dose increase (e.g., every $2$ to $4$ weeks), then spaced out to every $4$ to $8$ weeks, and eventually to every $8$ to $12$ weeks once the patient is on a stable, well-tolerated dose. A frequency of every $4$–$8$ weeks is appropriate during the titration phase.\n\n**Evaluation of Provided Options:**\n\n**A. Start $15$ mg orally once weekly (approximately $0.21$ mg/kg/week), co-prescribe folic acid $1$ mg daily (omit on the methotrexate day), and titrate by $2.5$ mg every $2$ weeks as tolerated to a maximum of $25$ mg/week; consider switching to subcutaneous administration if absorption or tolerability become limiting beyond $15$ mg; monitor CBC, liver function tests (LFTs), and serum creatinine every $4$–$8$ weeks.**\n- **Initial Dose:** $15$ mg once weekly is appropriate and within the given range.\n- **Supplementation:** Folic acid $1$ mg daily (withholding on the MTX day) is a standard and correct regimen.\n- **Titration:** Escalating by $2.5$ mg every $2$ weeks to a max of $25$ mg is a safe and standard protocol.\n- **Route:** The provision to switch to subcutaneous is correct and addresses the principle of saturable absorption.\n- **Monitoring:** Monitoring CBC, LFTs, and creatinine every $4$–$8$ weeks is the correct and safe frequency for initiation and titration.\n- **Verdict: Correct.** This option fully aligns with all the established principles of care outlined in the problem.\n\n**B. Start $10$ mg daily, co-prescribe folic acid $5$ mg twice daily, and escalate by $5$ mg/day each week to a maximum of $25$ mg/day; monitor CBC and LFTs every $6$ months.**\n- **Dosing Regimen:** Daily administration is fundamentally incorrect and dangerous for an inflammatory condition, violating the \"once-weekly\" principle. This represents a high-dose cytotoxic regimen, not low-dose immunomodulation.\n- **Titration:** Escalating a daily dose is extremely hazardous.\n- **Monitoring:** Monitoring every $6$ months is grossly inadequate and unsafe.\n- **Verdict: Incorrect.** This regimen is inappropriate and poses a high risk of severe toxicity.\n\n**C. Start $7.5$ mg once weekly without folate, escalate by $7.5$ mg each week to $45$ mg/week; obtain weekly labs until stable.**\n- **Initial Dose:** $7.5$ mg is below the specified starting range of $10$-$15$ mg.\n- **Supplementation:** Omitting folate (\"without folate\") is a direct violation of a key safety principle and increases the risk of side effects.\n- **Titration and Max Dose:** Escalating by $7.5$ mg weekly is too rapid. A maximum dose of $45$ mg/week is excessive and well above the standard maximum of $25$ mg/week, increasing toxicity risk.\n- **Verdict: Incorrect.** This option is unsafe due to the lack of folate, rapid titration, and excessive target dose.\n\n**D. Start at the target dose of $25$ mg once weekly with leucovorin (folinic acid) $15$ mg given $24$ hours later and no titration; check labs quarterly only if symptoms occur.**\n- **Titration:** Starting at the maximum dose with \"no titration\" violates the principle of safe up-titration. This increases the risk of acute intolerance and toxicity.\n- **Monitoring:** Monitoring only quarterly and only if symptoms occur is dangerously inadequate. Laboratory abnormalities often precede clinical symptoms.\n- **Verdict: Incorrect.** The lack of titration and insufficient monitoring make this option unsafe.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Effective immunosuppression is increasingly moving towards personalized medicine. For azathioprine, a key immunomodulator, pre-treatment genetic testing for enzymes like thiopurine S-methyltransferase (TPMT) is now the standard of care to prevent severe toxicity. This exercise demonstrates how to integrate pharmacogenetic data into clinical decision-making, requiring you to calculate a risk-adjusted starting dose and justify a cautious titration strategy for a patient with reduced drug metabolism. ",
            "id": "4683381",
            "problem": "A $28$-year-old adult with noninfectious posterior uveitis requires a steroid-sparing agent. You plan to initiate azathioprine. Baseline hepatic and renal function are within reference ranges. Genotyping shows thiopurine S-methyltransferase (TPMT) intermediate metabolizer status and nudix hydrolase $15$ (NUDT$15$) normal activity. Assume oral bioavailability remains approximately constant across low-dose ranges and that azathioprine and its active metabolites exhibit dose-proportional (linear) pharmacokinetics over the contemplated starting-dose interval.\n\nUse the following foundational facts:\n- Under linear pharmacokinetics, the average steady-state concentration $C_{\\mathrm{ss,avg}}$ over a dosing interval is proportional to dose and inversely proportional to clearance, specifically $C_{\\mathrm{ss,avg}} \\propto \\frac{\\text{Dose}}{Cl}$ when bioavailability and dosing interval are unchanged.\n- TPMT catalyzes a major inactivation pathway of thiopurines; TPMT intermediate metabolizers have reduced enzymatic activity, which effectively lowers the apparent clearance through this pathway and increases formation of $6$-thioguanine nucleotides that drive both efficacy and myelotoxicity risk.\n- In clinical practice for uveitis, a conservative initial azathioprine strategy for TPMT intermediate metabolizers selects the lower end of an evidence-supported starting range to target similar exposure with reduced toxicity risk.\n\nFor a $60$ kg patient with TPMT intermediate metabolizer status, use the lower bound of an evidence-supported starting range of $0.5$ to $1$ mg/kg/day to compute the initial azathioprine daily dose. Round your final numeric answer to two significant figures and express it in milligrams per day (mg/day). Then, based on the pharmacokinetic proportionality above and the mechanism of TPMT, justify why a slower up-titration is warranted from this starting dose to reach a maintenance dose.",
            "solution": "The problem statement has been validated and is deemed valid. It is scientifically grounded in established principles of pharmacogenetics and pharmacokinetics, well-posed, objective, and contains all necessary information to derive a solution.\n\nThe problem asks for two components: first, the calculation of an initial daily dose of azathioprine for a specific patient, and second, a justification for the clinical strategy of slow dose titration in this patient context.\n\n**Part 1: Calculation of the Initial Daily Dose**\n\nThe problem provides the following information for the calculation:\n- Patient weight: $60$ kg\n- Patient genotype: Thiopurine S-methyltransferase (TPMT) intermediate metabolizer\n- Evidence-supported starting dose range for azathioprine: $0.5$ mg/kg/day to $1$ mg/kg/day\n- Clinical strategy: For a TPMT intermediate metabolizer, the initial dose should be selected from the lower end of the supported range to mitigate toxicity risk.\n\nWe are instructed to use the lower bound of the given range.\nThe lower bound of the dose range is $0.5$ mg/kg/day.\n\nThe initial daily dose is calculated by multiplying the patient's weight by the selected dose per unit weight.\nLet $D_{\\text{initial}}$ be the initial daily dose, $W$ be the patient's weight, and $d_{\\text{rate}}$ be the dosing rate.\n\n$$D_{\\text{initial}} = W \\times d_{\\text{rate}}$$\n\nSubstituting the given values:\n$W = 60$ kg\n$d_{\\text{rate}} = 0.5$ mg/kg/day\n\n$$D_{\\text{initial}} = 60 \\, \\text{kg} \\times 0.5 \\, \\frac{\\text{mg}}{\\text{kg} \\cdot \\text{day}} = 30 \\, \\frac{\\text{mg}}{\\text{day}}$$\n\nThe problem requires the answer to be rounded to two significant figures. The number $30$ can be represented as $3.0 \\times 10^1$, which has two significant figures. Therefore, the calculated dose of $30$ mg/day meets the requirement.\n\n**Part 2: Justification for Slower Up-Titration**\n\nThe justification for a slower up-titration schedule from this reduced starting dose is based on the pharmacokinetic and pharmacodynamic principles provided.\n\n1.  **Pharmacokinetic Basis:** The problem states that the average steady-state concentration ($C_{\\mathrm{ss,avg}}$) is proportional to the ratio of the dose ($Dose$) to the drug's clearance ($Cl$):\n    $$C_{\\mathrm{ss,avg}} \\propto \\frac{Dose}{Cl}$$\n    This relationship holds for a constant dosing interval and bioavailability.\n\n2.  **Genetic Influence on Clearance:** Azathioprine is a prodrug that is converted to active metabolites, including $6$-thioguanine nucleotides ($6$-TGNs). A major pathway for inactivating the precursor thiopurines is catalyzed by the enzyme TPMT. The patient is a TPMT intermediate metabolizer, meaning they have genetically determined reduced TPMT enzymatic activity compared to a normal metabolizer. This reduced activity leads to a decrease in the rate of drug inactivation. A reduced inactivation rate is equivalent to a lower apparent systemic clearance ($Cl$) of the drug.\n\n3.  **Impact on Drug Exposure:** According to the pharmacokinetic proportionality, a lower clearance ($Cl$) will result in a higher average steady-state concentration ($C_{\\mathrm{ss,avg}}$) of the active metabolites for any given dose. Therefore, a TPMT intermediate metabolizer will have higher concentrations of $6$-TGNs compared to a normal metabolizer receiving the same dose of azathioprine.\n\n4.  **Toxicity Risk:** The problem states that $6$-TGNs are responsible for both the therapeutic effects (immunosuppression) and the primary dose-limiting toxicity (myelosuppression). The elevated $6$-TGN levels in a TPMT intermediate metabolizer significantly increase the risk of severe myelosuppression if standard doses (e.g., $1$ to $2.5$ mg/kg/day) are used for initiation. The calculated starting dose of $30$ mg/day (or $0.5$ mg/kg/day) is a risk-mitigation strategy to target a safer initial drug exposure.\n\n5.  **Rationale for Slow Titration:** While the reduced starting dose lowers the initial risk, the optimal maintenance dose that balances efficacy and safety is still unknown. There is inter-individual variability in the degree of clearance reduction even among intermediate metabolizers. A slow up-titration from the conservative starting dose is a crucial safety measure. It allows the clinician to gradually increase the dose while closely monitoring for signs of toxicity (e.g., through regular complete blood count monitoring) and clinical efficacy. This methodical approach enables the personalization of the dose to the individual patient's tolerance and response, minimizing the risk of a sudden, dangerous accumulation of toxic metabolites that could occur with a more rapid dose escalation. This approach ensures that a therapeutic concentration is achieved without overshooting into a toxic range.",
            "answer": "$$\\boxed{30}$$"
        },
        {
            "introduction": "While initiating therapy requires care, managing complications is an equally critical skill, especially when using combination regimens. This final practice presents a common but serious scenario: myelosuppression in a patient on dual-agent therapy. You will be asked to navigate this challenge by systematically applying a safety algorithm based on toxicity grading, demonstrating how to prioritize patient safety by holding and modifying treatment in a structured, evidence-based manner. ",
            "id": "4683314",
            "problem": "A $36$-year-old woman with noninfectious intermediate uveitis has been stable on dual immunomodulatory therapy for $8$ months: methotrexate $25$ mg once weekly and azathioprine $150$ mg once daily. Her baseline complete blood count was normal. At today’s visit, she reports mild fatigue but no fever, mucosal bleeding, or infections. Her complete blood count shows the following: Absolute Neutrophil Count (ANC) $0.8 \\times 10^9/\\text{L}$ and platelet count $65 \\times 10^9/\\text{L}$. Liver enzymes and creatinine are within normal limits.\n\nUse the following foundational facts to reason to an appropriate dose-adjustment plan:\n- Common Terminology Criteria for Adverse Events (CTCAE) hematologic grading: neutropenia Grade $3$ corresponds to ANC $0.5$ to $<1.0 \\times 10^9/\\text{L}$; thrombocytopenia Grade $2$ corresponds to platelets $50$ to $<75 \\times 10^9/\\text{L}$; Grade $3$ platelets are $25$ to $<50 \\times 10^9/\\text{L}$.\n- Infection risk rises steeply when ANC $<1.0 \\times 10^9/\\text{L}$ and bleeding risk rises as platelets fall $<75 \\times 10^9/\\text{L}$; management prioritizes safety by holding or reducing myelosuppressive drugs when cytopenias are Grade $\\geq 3$.\n- In nonmalignant immunosuppression, a conservative and commonly applied approach for Grade $3$ hematologic toxicity is to temporarily hold myelosuppressive agents and, on recovery to safer thresholds, resume with approximately $50\\%$ dose reduction of the culpable myelosuppressive burden to reduce recurrence risk while maintaining disease control.\n\nAssume the patient has no known thiopurine methyltransferase (TPMT) or nudix hydrolase $15$ (NUDT15) deficiency and no intercurrent infection. Which of the following dose-adjustment plans best applies a percentage-decrement algorithm keyed to the more severe cytopenia while balancing safety and uveitis control?\n\nA. Hold both agents until recovery to ANC $\\geq 1.5 \\times 10^9/\\text{L}$ and platelets $\\geq 100 \\times 10^9/\\text{L}$; then resume methotrexate at $12.5$ mg once weekly and azathioprine at $75$ mg once daily.\n\nB. Continue methotrexate at $25$ mg once weekly; reduce azathioprine to $100$ mg once daily; add folic acid; recheck labs in $2$ weeks.\n\nC. Hold azathioprine; when counts recover, resume azathioprine at $50$ mg once daily with methotrexate unchanged at $25$ mg once weekly.\n\nD. Reduce methotrexate to $10$ mg once weekly and discontinue azathioprine indefinitely; add prophylactic oral antibiotics; recheck labs in $4$ weeks.",
            "solution": "The user has provided a clinical scenario and a set of foundational principles to arrive at a management decision. The task is to validate the problem and then determine the most appropriate course of action from the given options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n- **Patient Profile**: A $36$-year-old woman with noninfectious intermediate uveitis.\n- **Treatment History**: Stable for $8$ months on dual immunomodulatory therapy.\n- **Medications**: Methotrexate $25$ mg once weekly and azathioprine $150$ mg once daily.\n- **Baseline Labs**: Normal complete blood count.\n- **Current Symptoms**: Mild fatigue; no fever, mucosal bleeding, or infections.\n- **Current Laboratory Data**:\n    - Absolute Neutrophil Count (ANC): $0.8 \\times 10^9/\\text{L}$\n    - Platelet count: $65 \\times 10^9/\\text{L}$\n    - Liver enzymes and creatinine: within normal limits.\n- **Assumptions**: No known thiopurine methyltransferase (TPMT) or nudix hydrolase $15$ (NUDT15) deficiency; no intercurrent infection.\n- **Foundational Facts for Reasoning**:\n    1.  **CTCAE Grading**:\n        - Neutropenia Grade $3$: ANC $0.5$ to $<1.0 \\times 10^9/\\text{L}$.\n        - Thrombocytopenia Grade $2$: Platelets $50$ to $<75 \\times 10^9/\\text{L}$.\n        - Thrombocytopenia Grade $3$: Platelets $25$ to $<50 \\times 10^9/\\text{L}$.\n    2.  **Risk & General Management**:\n        - Infection risk increases steeply when ANC $<1.0 \\times 10^9/\\text{L}$.\n        - Bleeding risk increases as platelets fall $<75 \\times 10^9/\\text{L}$.\n        - Management prioritizes holding or reducing myelosuppressive drugs for Grade $\\geq 3$ cytopenias.\n    3.  **Specific Algorithm for Grade $3$ Toxicity**:\n        - Temporarily hold myelosuppressive agents.\n        - Upon recovery to safer thresholds, resume with an approximately $50\\%$ dose reduction of the culpable myelosuppressive burden.\n- **Question**: Which of the following dose-adjustment plans best applies a percentage-decrement algorithm keyed to the more severe cytopenia while balancing safety and uveitis control?\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is scientifically sound. It presents a realistic clinical case involving known side effects (myelosuppression) of standard immunosuppressive drugs (methotrexate, azathioprine). The laboratory values, CTCAE grading criteria, and management principles are all consistent with established medical practice in rheumatology and ophthalmology.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data (patient condition, medications, lab results) and a clear, explicit set of rules (\"foundational facts\") to follow for deriving the solution. The question is specific, asking to apply a defined algorithm.\n- **Objective**: The problem is objective, using precise clinical and laboratory terminology. The provided \"foundational facts\" constitute an objective framework, removing subjectivity from the decision-making process.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. It is scientifically grounded, well-posed, and objective. I will now proceed with the solution derivation.\n\n### Solution Derivation\n\nThe derivation proceeds by a systematic application of the provided foundational facts to the patient's data.\n\n1.  **Assess and Grade the Cytopenias**:\n    - The patient's Absolute Neutrophil Count (ANC) is $0.8 \\times 10^9/\\text{L}$. According to the provided CTCAE criteria, an ANC in the range of $0.5$ to $<1.0 \\times 10^9/\\text{L}$ constitutes **Grade $3$ neutropenia**.\n    - The patient's platelet count is $65 \\times 10^9/\\text{L}$. According to the provided CTCAE criteria, a platelet count in the range of $50$ to $<75 \\times 10^9/\\text{L}$ constitutes **Grade $2$ thrombocytopenia**.\n\n2.  **Identify the More Severe Cytopenia**:\n    - The problem specifies that the management algorithm should be \"keyed to the more severe cytopenia.\"\n    - Comparing Grade $3$ neutropenia to Grade $2$ thrombocytopenia, the Grade $3$ toxicity is more severe. Therefore, the management plan must follow the rule for Grade $3$ hematologic toxicity.\n\n3.  **Apply the Grade $3$ Toxicity Management Algorithm**:\n    - The rule for Grade $3$ toxicity states to \"temporarily hold myelosuppressive agents\". Both methotrexate and azathioprine are myelosuppressive agents. Therefore, both drugs must be held temporarily.\n    - The rule further states to resume therapy \"on recovery to safer thresholds\" with an \"approximately $50\\%$ dose reduction of the culpable myelosuppressive burden\". Since the patient is on dual therapy and both agents contribute to myelosuppression, the \"culpable myelosuppressive burden\" involves both drugs. A systematic application of a $50\\%$ reduction would apply to the dosage of each agent.\n    - **Original Doses**:\n        - Methotrexate: $25$ mg once weekly.\n        - Azathioprine: $150$ mg once daily.\n    - **Calculated Reduced Doses (50% reduction)**:\n        - Methotrexate: $0.50 \\times 25 \\text{ mg} = 12.5$ mg once weekly.\n        - Azathioprine: $0.50 \\times 150 \\text{ mg} = 75$ mg once daily.\n\n4.  **Synthesize the Complete Plan**:\n    - **Action 1**: Temporarily hold both methotrexate and azathioprine.\n    - **Action 2**: Monitor blood counts until they have recovered to safer levels (e.g., ANC $\\geq 1.5 \\times 10^9/\\text{L}$ and platelets $\\geq 100 \\times 10^9/\\text{L}$, which represent recovery to Grade $0$ or $1$ levels and are common clinical targets).\n    - **Action 3**: Resume both medications at $50\\%$ of their original doses: methotrexate at $12.5$ mg weekly and azathioprine at $75$ mg daily.\n\n### Option-by-Option Analysis\n\nNow, I will evaluate each option against this logically derived plan.\n\n**A. Hold both agents until recovery to ANC $\\geq 1.5 \\times 10^9/\\text{L}$ and platelets $\\geq 100 \\times 10^9/\\text{L}$; then resume methotrexate at $12.5$ mg once weekly and azathioprine at $75$ mg once daily.**\n- This plan correctly implements the \"hold\" directive for both myelosuppressive agents in response to Grade $3$ toxicity.\n- It specifies reasonable and safe recovery thresholds before resuming therapy.\n- It correctly applies the \"approximately $50\\%$ dose reduction\" rule to both agents (methotrexate $25 \\text{ mg} \\rightarrow 12.5 \\text{ mg}$; azathioprine $150 \\text{ mg} \\rightarrow 75 \\text{ mg}$).\n- This plan aligns perfectly with the derivation.\n- **Verdict: Correct**\n\n**B. Continue methotrexate at $25$ mg once weekly; reduce azathioprine to $100$ mg once daily; add folic acid; recheck labs in $2$ weeks.**\n- This plan violates the primary rule for Grade $3$ toxicity, which is to \"temporarily hold myelosuppressive agents\". It continues methotrexate at full dose, posing an unacceptable risk given the ANC is already below the high-risk threshold of $1.0 \\times 10^9/\\text{L}$.\n- The reduction of azathioprine is not $50\\%$.\n- **Verdict: Incorrect**\n\n**C. Hold azathioprine; when counts recover, resume azathioprine at $50$ mg once daily with methotrexate unchanged at $25$ mg once weekly.**\n- This plan also violates the \"hold\" rule by continuing methotrexate at its full dose despite Grade $3$ neutropenia.\n- It arbitrarily assigns culpability to only one of two myelosuppressive agents.\n- The resumption dose of azathioprine ($50$ mg) represents a $66.7\\%$ reduction, not the specified \"approximately $50\\%$\".\n- **Verdict: Incorrect**\n\n**D. Reduce methotrexate to $10$ mg once weekly and discontinue azathioprine indefinitely; add prophylactic oral antibiotics; recheck labs in $4$ weeks.**\n- This plan does not \"hold\" the medication but rather continues methotrexate, violating the safety-first principle for Grade $3$ toxicity.\n- Discontinuing azathioprine \"indefinitely\" is an overly aggressive and potentially permanent change, which may compromise long-term uveitis control and contradicts the principle of resuming therapy at a reduced dose.\n- A $4$-week follow-up interval is too long for managing acute Grade $3$ neutropenia.\n- **Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}